Drug intelligence / Profile preview

GO306

Development stage: Phase 1
Lead developer: GeneSail Biotech
Modality: Oncolytic Viruses → Oncolytic Therapeutics
Administration: Intravenous, Intratumoral

Overview

GO306 is a recombinant oncolytic vaccinia virus developed by GeneSail Biotech. It is designed as an oncolytic virus therapy, which means it selectively infects and destroys cancer cells while sparing normal tissue. The drug is being investigated for use in refractory solid tumors, but its precise mechanism of action and molecular targets have not been publicly disclosed. As of early 2025, the highest development status reported for GO306 is IND (Investigational New Drug) application, indicating it has not yet entered advanced clinical trials[1][9][2].

Targets

TNFRSF9 (CD137 extracellular domain)PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on GO306.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GO306.

Explore the full profile